Arbutus Biopharma (ABUS) Proxy filing summary

Executive summary

• The annual meeting is scheduled for May 26, 2026, with proxy materials available online and by request.

• Shareholders are encouraged to vote via internet, phone, mail, or in person, with detailed instructions provided.

• The record date for voting eligibility is March 30, 2026, with 196,939,679 common shares outstanding.

Voting matters and shareholder proposals

• Shareholders will vote on: election of five directors, approval of the 2026 Omnibus Share and Incentive Plan, advisory say-on-pay for executive compensation, and appointment of EY as auditor.

• Board recommends voting for all director nominees and for all other proposals.

• Shareholder proposals for the 2027 meeting must be submitted by February 25, 2027 (BCBCA) or December 15, 2026 (SEC Rule 14a-8).

Board of directors and corporate governance

• Board consists of five directors, with four deemed independent; CEO also serves as Chair.

• Board committees include Audit, Compensation, and Corporate Governance/Nominating, all with independent members.

• Corporate governance guidelines and code of conduct are in place, with annual board and committee evaluations.

• Shareholders can nominate directors following advance notice and universal proxy rules.